The collaboration aims to expedite the development of an immuno-oncology product designed to treat specific cancers
Traverse Biotech, Genmab sign deal to develop novel cancer bispecific antibody. (Credit: fernando zhiminaicela from Pixabay)
Traverse Biotech, a US-based biotechnology firm, has entered into a license agreement with Genmab under which Traverse will develop and commercialise a bispecific antibody designed for cancer immunotherapy.
The antibody, created using Genmab’s proprietary DuoBody bispecific antibody technology platform, is intended as a targeted treatment for cancers that express a specific, undisclosed tumour-associated antigen.
The bispecific antibody’s mechanism of action involves directing T cell-mediated cytotoxicity against solid and liquid tumours expressing the specified tumour-associated antigen.
Under the terms of the license agreement, Traverse will leverage its operational and development expertise to advance and bring the bispecific antibody programme to market.
The collaboration intends to provide a novel immuno-oncology product to patients. Genmab’s DuoBody technology, which has served as the foundation for four FDA-approved bispecific medicines, will play a crucial role in this endeavour.
Traverse Biotech CEO Brandy Houser said: “We are highly motivated to work with a product candidate derived from Genmab’s state-of-the-art bispecific technology.”
Traverse Biotech’s primary focus lies in the late-stage preclinical and early-clinical development of immunotherapy products that have been de-risked. These products are sourced from various platforms and originate from selected international biopharmaceutical companies. Traverse Biotech secures worldwide rights for the development and commercialization of each product within its pipeline.
Their unique partnership model allows them to collaborate with biopharmaceutical companies that possess promising product candidates with validated manufacturing and clinical platforms. Through these partnerships, Traverse Biotech aims to accelerate the therapeutic development of each asset, typically through an initial clinical proof-of-concept study.
One of the distinguishing features of Traverse Biotech is its flexible and lean operating structure, which is designed to expedite development while also reducing costs across all phases of product development. Ultimately, the goal is to deliver these therapies to patients in a timelier manner.